AMT Receives Orphan Drug Designation For Porphyria
Orphan drug designation for AIP allows AMT to market in Europe for ten years, following marketing approval for AMT-021 from the European Union. Sander van Deventer, CEO, AMT,
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi.